Amgen Inc. Payment for Debt Extinguishment or Debt Prepayment Cost
Amgen Inc. (AMGN) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $233.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2026-08-05
- Amgen Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2026-03-31 was $233.00M, a 22.59% decline year-over-year.
- Amgen Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2025-12-31 was $0.00.
- Amgen Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2025-09-30 was $81.00M, a 67.47% decline year-over-year.
- Amgen Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2025 was $683.00M, a 3.64% increase from fiscal 2024.
- Amgen Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2024 was $659.00M, a 1.85% increase from fiscal 2023.
- Amgen Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $647.00M, a 117.85% increase from fiscal 2022.
- Amgen Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2022 was $297.00M.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $233.00M 10-Q · filed 2026-08-05 | $233.00M derived: sum of 3 quarters · filed 2026-08-05 | $314.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $233.00M 10-Q · filed 2026-05-01 | $233.00M derived: sum of 2 quarters · filed 2026-05-01 | $314.00M derived: sum of 3 quarters · filed 2026-05-01 | $615.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $81.00M derived: sum of 2 quarters · filed 2026-02-13 | $382.00M derived: sum of 3 quarters · filed 2026-08-05 | $683.00M 10-K · filed 2026-02-13 |
| 2025-09-30 | $81.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $382.00M derived: sum of 2 quarters · filed 2026-08-05 | $683.00M 10-Q · filed 2025-11-05 | $683.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $301.00M 10-Q · filed 2026-08-05 | $602.00M 10-Q · filed 2026-08-05 | $602.00M derived: sum of 3 quarters · filed 2026-08-05 | $851.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $301.00M 10-Q · filed 2026-05-01 | $301.00M derived: sum of 2 quarters · filed 2026-05-01 | $550.00M derived: sum of 3 quarters · filed 2026-05-01 | $550.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $249.00M derived: sum of 2 quarters · filed 2026-02-13 | $249.00M derived: sum of 3 quarters · filed 2026-02-13 | $659.00M 10-K · filed 2026-02-13 |
| 2024-09-30 | $249.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $249.00M derived: sum of 2 quarters · filed 2025-11-05 | $659.00M 10-Q · filed 2025-11-05 | $756.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $410.00M 10-Q · filed 2025-08-06 | $507.00M derived: sum of 3 quarters · filed 2026-02-13 | $637.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $410.00M 10-Q · filed 2025-05-02 | $507.00M derived: sum of 2 quarters · filed 2026-02-13 | $637.00M derived: sum of 3 quarters · filed 2026-02-13 | $637.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $97.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $227.00M derived: sum of 2 quarters · filed 2026-02-13 | $227.00M derived: sum of 3 quarters · filed 2026-02-13 | $647.00M 10-K · filed 2026-02-13 |
| 2023-09-30 | $130.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $130.00M derived: sum of 2 quarters · filed 2024-10-31 | $550.00M 10-Q · filed 2024-10-31 | $550.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $420.00M 10-Q · filed 2024-08-07 | $420.00M derived: sum of 3 quarters · filed 2025-02-14 | $717.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $420.00M 10-Q · filed 2024-05-03 | $420.00M derived: sum of 2 quarters · filed 2025-02-14 | $717.00M derived: sum of 3 quarters · filed 2025-02-14 | $717.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $297.00M derived: sum of 2 quarters · filed 2025-02-14 | $297.00M derived: sum of 3 quarters · filed 2025-02-14 | $297.00M 10-K · filed 2025-02-14 |
| 2022-09-30 | $297.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $297.00M derived: sum of 2 quarters · filed 2023-10-31 | $297.00M 10-Q · filed 2023-10-31 | $297.00M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $0.00 10-Q · filed 2023-08-04 | $0.00 derived: sum of 3 quarters · filed 2024-02-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-04-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-14 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $0.00 10-K · filed 2024-02-14 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |